Methylation of miR-34a, miR-34b/c, miR-124-1 and miR-203 in Ph-negative myeloproliferative neoplasms

Journal of Translational Medicine

Kit Fai Wong¹  Hans G Drexler²  Tsz Kin Fung³  Kwan Yeung Wong³  Thomas S Wan⁴  Chor Sang Chim³ 

[1] Department of Pathology, Queen Elizabeth Hospital, Hong Kong;Department of Human and Animal Cell Cultures, DSMZ - German Collection of Microorganisms and Cell Cultures, Inhoffenstr. 7B 38126 Braunschweig, Germany;Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong;Department of Pathology, Queen Mary Hospital, The University of Hong Kong, Hong Kong

关键词: Ph-negative myeloproliferative neoplasm;    hypermethylation;    tumor suppressor;    microRNA;   

Others  :  1207821
DOI  :  10.1186/1479-5876-9-197

 received in 2011-04-07, accepted in 2011-11-14,  发布年份 2011

【 摘 要 】

Background

MicroRNA (miR) miR-34a, -34b/c, -124-1 and -203 are tumor suppressor miRs implicated in carcinogenesis.

Methods

We studied DNA methylation of these miRs in Philadelphia-negative (Ph-ve) myeloproliferative neoplasms (MPNs). Methylation-specific PCR (MSP), verified by direct sequencing of the methylated MSP products, was performed in cell lines, normal controls and diagnostic marrow samples of patients with MPNs.

Results

Methylation of these miRs was absent in the normal controls. miR-34b/c were homozygously methylated in HEL cells but heterozygously in MEG-01. In HEL cells, homozygous miR-34b/c methylation was associated with miR silencing, and 5-aza-2'-deoxycytidine treatment led to re-expression of both miR-34b and miR-34c, consistent with that both miRs are under the regulation of the same promoter CpG island. miR-34a was heterozygously methylated in MEG-01 and K-562. miR-203 was completely unmethylated in K-562 and SET-2 but no MSP amplification was found in both HEL and MEG-01, suggestive of miR deletion. In primary samples, four each had miR-34b/c and -203 methylation, in which two had concomitant methylation of miR-34b/c and -203. miR-34a was methylated in one patient and none had methylation of miR-124-1. Seven patients (15.6%) had methylation of at least one of the four miRs. miR methylation did not correlate with clinical parameters, disease complications or JAK2 V617F mutation.

Conclusion

This is the first report of miR hypermethylation in MPNs. miR-203 hypermethylation is not specific to Ph+ve leukemias but also present in Ph-ve MPNs. miR-34b/c methylation was associated with reversible miR silencing. There was no correlation of miR methylation with clinical demographic data or outcome.

【 授权许可】

   
2011 Chim et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Tefferi A, Thiele J, Orazi A, Kvasnicka HM, Barbui T, Hanson CA, Barosi G, Verstovsek S, Birgegard G, Mesa R, et al.: Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood 2007, 110:1092-1097.
• [2]Chim CS, Kwong YL, Lie AKW, Ma SK, Chan CC, Wong LG, San Kho BC, Lee HK, Sim JPY, Chan CH, et al.: Long-term Outcome of 231 Patients With Essential Thrombocythemia: Prognostic Factors for Thrombosis, Bleeding, Myelofibrosis, and Leukemia. Arch Intern Med 2005, 165:2651-2658.
• [3]Chim CS, Kwong YL, Chan PT, Raymond L: Polycythemia vera in Chinese patients: Thirty-six years of experience. American Journal of Hematology 1997, 56:59-62.
• [4]Chim CS, Liang R, Kwong YL: Hypermethylation of gene promoters in hematological neoplasia. Hematol Oncol 2002, 20:167-176.
• [5]Chen CZ: MicroRNAs as Oncogenes and Tumor Suppressors. N Engl J Med 2005, 353:1768-1771.
• [6]Calin GA, Croce CM: MicroRNA signatures in human cancers. Nat Rev Cancer 2006, 6:857-866.
• [7]Esquela-Kerscher A, Slack FJ: Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer 2006, 6:259-269.
• [8]Lodygin D, Tarasov V, Epanchintsev A, Berking C, Knyazeva T, Korner H, Knyazev P, Diebold J, Hermeking H: Inactivation of miR-34a by aberrant CpG methylation in multiple types of cancer. Cell Cycle 2008, 7:2591-2600.
• [9]Chim CS, Wong KY, Qi Y, Loong F, Lam WL, Wong LG, Jin DY, Costello JF, Liang R: Epigenetic inactivation of the miR-34a in hematological malignancies. Carcinogenesis 2010, 31:745-750.
• [10]Pigazzi M, Manara E, Baron E, Basso G: miR-34b Targets Cyclic AMP-Responsive Element Binding Protein in Acute Myeloid Leukemia. Cancer Res 2009, 69:2471-2478.
• [11]Agirre X, Vilas-Zornoza A, Jimenez-Velasco A, Martin-Subero JI, Cordeu L, Garate L, San Jose-Eneriz E, Abizanda G, Rodriguez-Otero P, Fortes P, et al.: Epigenetic Silencing of the Tumor Suppressor MicroRNA Hsa-miR-124a Regulates CDK6 Expression and Confers a Poor Prognosis in Acute Lymphoblastic Leukemia. Cancer Res 2009, 69:4443-4453.
• [12]Bueno MJ, Perez de Castro I, Gomez de Cedron M, Santos J, Calin GA, Cigudosa JC, Croce CM, Fernandez-Piqueras J, Malumbres M: Genetic and Epigenetic Silencing of MicroRNA-203 Enhances ABL1 and BCR-ABL1 Oncogene Expression. Cancer Cell 2008, 13:496-506.
• [13]Chim CS, Fung TK, Cheung WC, Liang R, Kwong YL: SOCS1 and SHP1 hypermethylation in multiple myeloma: implications for epigenetic activation of the Jak/STAT pathway. Blood 2004, 103:4630-4635.
• [14]Chim CS, Liang R, Tam CYY, Kwong YL: Methylation of p15 and p16 Genes in Acute Promyelocytic Leukemia: Potential Diagnostic and Prognostic Significance. J Clin Oncol 2001, 19:2033-2040.
• [15]Livak KJ, Schmittgen TD: Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2-[Delta][Delta]CT Method. Methods 2001, 25:402-408.
• [16]Bruchova H, Yoon D, Agarwal AM, Mendell J, Prchal JT: Regulated expression of microRNAs in normal and polycythemia vera erythropoiesis. Experimental Hematology 2007, 35:1657-1667.
• [17]Garzon R, Pichiorri F, Palumbo T, Iuliano R, Cimmino A, Aqeilan R, Volinia S, Bhatt D, Alder H, Marcucci G, et al.: MicroRNA fingerprints during human megakaryocytopoiesis. Proceedings of the National Academy of Sciences of the United States of America 2006, 103:5078-5083.
• [18]Chim CS, Tam CYY, Liang R, Kwong YL: Methylation of p15 and p16 genes in adult acute leukemia. Cancer 2001, 91:2222-2229.
• [19]Chim CS, Wong ASY, Kwong YL: Epigenetic inactivation of the CIP/KIP cell-cycle control pathway in acute leukemias. American Journal of Hematology 2005, 80:282-287.
• [20]Chim CS, Wong SY, Pang A, Chu P, Lau JS, Wong KF, Kwong YL: Aberrant promoter methylation of the retinoic acid receptor alpha gene in acute promyelocytic leukemia. Leukemia 2005, 19:2241-2246.
• [21]Chim CS, Wong ASY, Kwong YL: Epigenetic dysregulation of the Jak/STAT pathway by frequent aberrant methylation of SHP1 but not SOCS1 in acute leukaemias. Annals of Hematology 2004, 83:527-532.
• [22]Chim CS, Wong SY, Kwong YL: Aberrant gene promoter methylation in acute promyelocytic leukaemia: profile and prognostic significance. Br J Haematol 2003, 122:571-578.
• [23]Capello D, Deambrogi C, Rossi D, Lischetti T, Piranda D, Cerri M, Spina V, Rasi S, Gaidano G, Lunghi M: Epigenetic inactivation of suppressors of cytokine signalling in Philadelphia-negative chronic myeloproliferative disorders. British Journal of Haematology 2008, 141:504-511.
• [24]Quentmeier H, Geffers R, Jost E, MacLeod RAF, Nagel S, Rohrs S, Romani J, Scherr M, Zaborski M, Drexler HG: SOCS2: inhibitor of JAK2V617F-mediated signal transduction. Leukemia 2008, 22:2169-2175.
• [25]Fourouclas N, Li J, Gilby DC, Campbell PJ, Beer PA, Boyd EM, Goodeve AC, Bareford D, Harrison CN, Reilly JT, et al.: Methylation of the suppressor of cytokine signaling 3 gene (SOCS3) in myeloproliferative disorders. Haematologica 2008, 93:1635-1644.
• [26]Chim CS, Fung TK, Liang R: Methylation of cyclin-dependent kinase inhibitors, XAF1, JUNB, CDH13 and soluble Wnt inhibitors in essential thrombocythaemia. Journal of Clinical Pathology 2010, 63:518-521.
• [27]Wong KY, So CC, Loong F, Chung LP, Lam WWL, Liang R, Li GKH, Jin D-Y, Chim CS: Epigenetic Inactivation of the miR-124-1 in Haematological Malignancies. PLoS One 2011, 6:e19027.
• [28]Wong KY, Yu L, Chim CS: DNA methylation of tumor suppressor miRNA genes: a lesson from the miR-34 family. Epigenomics 2011, 3:83-92.
• [29]Wong KY, Liang R, So CC, Jin DY, Costello JF, Chim CS: Epigenetic silencing of MIR203 in multiple myeloma. British Journal of Haematology 2011, 154:569-578.
• [30]Drexler HG: Guide to Leukemia-Lymphoma Cell Lines. 2nd edition. Braunschweig; 2010.
• [31]Wong KY, Yim RLH, So CC, Jin D-Y, Liang R, Chim CS: Epigenetic inactivation of the MIR34B/C in multiple myeloma. Blood 2011, 118:5901-5904.
• [32]Chim CS, Chan WWL, Pang A, Kwong YL: Preferential methylation of Wnt inhibitory factor-1 in acute promyelocytic leukemia: an independent poor prognostic factor. Leukemia 2006, 20:907-909.
• [33]Chim CS, Kwong YL: Adverse prognostic impact of CDKN2B hyper-methylation in acute promyelocytic leukemia. Leukemia & Lymphoma 2006, 47:815-825.
• [34]Lujambio A, Calin GA, Villanueva A, Ropero S, Sanchez-Cespedes M, Blanco D, Montuenga LM, Rossi S, Nicoloso MS, Faller WJ, et al.: A microRNA DNA methylation signature for human cancer metastasis. PNAS 2008. 0803055105
• [35]Toyota M, Suzuki H, Sasaki Y, Maruyama R, Imai K, Shinomura Y, Tokino T: Epigenetic Silencing of MicroRNA-34b/c and B-Cell Translocation Gene 4 Is Associated with CpG Island Methylation in Colorectal Cancer. Cancer Res 2008, 68:4123-4132.
• [36]Lujambio A, Ropero S, Ballestar E, Fraga MF, Cerrato C, Setien F, Casado S, Suarez-Gauthier A, Sanchez-Cespedes M, Gitt A, et al.: Genetic Unmasking of an Epigenetically Silenced microRNA in Human Cancer Cells. Cancer Res 2007, 67:1424-1429.
• [37]Chim CS, Wong KY, Leung CY, Chung LP, Hui PK, Chan SY, Yu L: Epigenetic inactivation of the hsa-miR-203 in haematological malignancies. Journal of Cellular and Molecular Medicine 2011, 15:2760-2767.